Dynamic42 receives Thüringer Gründerpreis 2018

7. December 2018 In News

Thuringian Founder’s Award – Dynamic42 GmbH honoured

On 04 December 2018, this year’s Thuringian Founder’s Prize was awarded in the historic Volksbad Jena. Dynamic42 GmbH was awarded 3rd place in category 1 “Business Plan”. The prize, endowed with €5,000, was presented by Thuringia’s Minister of Economic Affairs Wolfgang Tiefensee. “We are very happy to have received an early Christmas present. It seemed to have been a neck-and-neck race in the business plan category, as we heard from the IHK. All the nicer that we made it onto the winner’s podium,” says Dr. Knut Rennert, Managing Director of Dynamic42 GmbH. The Thuringian Ministry of Economy, Science and Digital Society (TMWWDG) provided a total of 75,000 € in prize money and the IHK Ostthüringen zu Gera and the Thuringian Centre for Start-ups and Entrepreneurship (ThEx) selected 11 winners from 69 applications in 4 categories.

We would like to thank all participants for a great competition and especially Ms Beate Seifarth (IHK) for the good organisation and support!

The complete award ceremony can be viewed here on Facebook.

Press Release | Dynamic42 launches Tumor Microenvironment Kit to advance complex in vitro cancer research

Dynamic42 GmbH announces the market launch of its Tumor Microenvironment (TME) Kit. The new product enables the creation of perfused 3D tumor models that reproduce the complexity of the human tumor microenvironment.

Press Release | Ohio Lumex Named Exclusive U.S. Distributor for Dynamic42’s Advanced Organ-on-Chip Technology

Ohio Lumex, a recognized leader in analytical solutions, is proud to announce a new partnership with German biotechnology company Dynamic42. Effective immediately, Ohio Lumex will serve as the exclusive distributor of Dynamic42’s innovative organ-on-chip technology in the United States.

Press Release | Tumour-on-chip model supports preclinical drug development on pancreatic cancer

Dynamic42 and Heinrich Heine University have developed a tumour-on-a-chip model that replicates the microenvironment of pancreatic ductal adenocarcinoma (PDAC). This 3D model allows for realistic drug testing and could accelerate the development of personalized therapies.

All News